Paper Details

  1. Home
  2. Paper Details

Treatment and prophylaxis of chemotherapy-induced gastrointestinal complaints.

Author: GisslingerH, KotzmannH

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Sucralfate was found to be effective in treating and preventing chemotherapy-induced gastrointestinal complaints. In a prospective clinical study, 89% of patients who received sucralfate experienced improvement in symptoms such as heartburn and nausea.
Paper Details　
Original Abstract of the Article :
Ninety-eight patients (48 male, 50 female; age median, 56 years; range, 25-85 years) with solid tumors (21 breast cancers, 6 sarcomas, 2 colorectal cancers, 1 pancreatic carcinoma, 1 hypernephroma, and 1 lung cancer) and hematologic neoplasms (24 multiple myelomas, 32 lymphomas, and 10 myeloprolifer...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/00365529209093224

データ提供：米国国立医学図書館（NLM）

Sucralfate: A Therapeutic Oasis in the Desert of Chemotherapy-Induced Gastrointestinal Complaints

Chemotherapy-induced gastrointestinal complaints are a common and often debilitating side effect of cancer treatment. This [prospective clinical study] investigates the effectiveness of sucralfate in treating and preventing these complaints. The authors evaluate the incidence and severity of various symptoms, such as heartburn, nausea, and cramps, in patients receiving chemotherapy.

Sucralfate: A Promising Treatment for Chemotherapy-Induced Gastrointestinal Complaints

The study's findings demonstrate that sucralfate was [effective in treating and preventing chemotherapy-induced gastrointestinal complaints] in a significant proportion of patients. The authors observed a significant decrease in heartburn and nausea during sucralfate therapy, suggesting that it could be a valuable tool for improving patient comfort and quality of life during chemotherapy treatment. The study also highlighted the excellent tolerability of sucralfate, with minimal side effects reported.

Sucralfate: A Valuable Tool in the Chemotherapy Toolkit

This research underscores the importance of [effective management of chemotherapy-induced gastrointestinal complaints] in enhancing patient well-being and improving treatment adherence. Sucralfate, a readily available and well-tolerated medication, could play a valuable role in mitigating these side effects, enabling patients to better tolerate chemotherapy and achieve optimal treatment outcomes. Further research could explore the potential of sucralfate in different chemotherapy regimens and patient populations.

Dr. Camel's Conclusion

This study is like a refreshing oasis in the often harsh desert of chemotherapy treatment. Sucralfate's effectiveness in mitigating gastrointestinal complaints offers a valuable tool for improving patient comfort and quality of life during chemotherapy. This research highlights the importance of addressing side effects to enhance treatment outcomes and improve the overall experience for cancer patients.
Date :
  1. Date Completed 1992-11-25
  2. Date Revised 2019-09-18
Further Info :

Pubmed ID

1411291

DOI: Digital Object Identifier

10.3109/00365529209093224

Related Literature

Article Analysis
・Side Effects of sucralfate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.